AU 409
Alternative Names: AU-409Latest Information Update: 23 Apr 2024
At a glance
- Originator Auransa
- Class Antineoplastics
- Mechanism of Action RNA-directed DNA polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Liver cancer; Solid tumours
Most Recent Events
- 18 Apr 2024 Phase-I clinical trials in Liver cancer (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (PO) (NCT06374485)
- 29 Mar 2023 Phase-I clinical trials in Liver cancer (Metastatic disease, Late-stage disease, Second-line therapy or greater) in USA (PO) (NCT05791448)
- 29 Mar 2023 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO) (NCT05791448)